The Role of Oncolytic Viral Therapy in the Management of Patients with Metastatic Melanoma
This CME program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option. Practical strategies for safely utilizing oncolytic viral therapies in clinical practice as well as best practices for engaging the interprofessional team will be relayed to the learner through an discussion-based format.
*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis and expert perspectives through conference coverage educational programs.
Upon completion of this activity, participants will be better able to do the following:
- Understand the metastatic melanoma science, including patient screening, diagnostic criteria, and the mechanism of action of oncolytic viral therapeutics.
- Analyze evidence based medicine for combination therapies that apply oncolytic viral therapeutics to the treatment of metastatic melanoma.
- Incorporate communication strategies and patient education into individualized treatment plans
to improve outcomes and the overall quality of life in patients with metastatic melanoma.
Michael Postow, MD (Course Chair)
Charlotte Ariyan, MD, PhD
Francesca Mistretta, BSN, RN, CMSRN
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Michael Postow, MD|
Consultant/Advisor: Array BioPharma; Bristol-Myers Squibb Company; Incyte Corporation; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation
|Charlotte Ariyan, MD, PhD|
Nothing to disclose.
|Francesca Mistretta, BSN, RN, CMSRN|
Nothing to disclose.
This activity has been supported by an independent educational grant from Amgen Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician